HomeCompareHBMHF vs MO

HBMHF vs MO: Dividend Comparison 2026

HBMHF yields 128.21% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBMHF wins by $11.51M in total portfolio value
10 years
HBMHF
HBMHF
● Live price
128.21%
Share price
$1.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.60M
Annual income
$4,575,129.27
Full HBMHF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — HBMHF vs MO

📍 HBMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBMHFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBMHF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBMHF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF
Annual income on $10K today (after 15% tax)
$10,897.44/yr
After 10yr DRIP, annual income (after tax)
$3,888,859.88/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, HBMHF beats the other by $3,863,224.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + MO for your $10,000?

HBMHF: 50%MO: 50%
100% MO50/50100% HBMHF
Portfolio after 10yr
$5.84M
Annual income
$2,302,644.21/yr
Blended yield
39.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

HBMHF
No analyst data
Altman Z
8.0
Piotroski
7/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys
0
MO buys
0
No recent congressional trades found for HBMHF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBMHFMO
Forward yield128.21%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$11.60M$80.1K
Annual income after 10y$4,575,129.27$30,159.17
Total dividends collected$10.60M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: HBMHF vs MO ($10,000, DRIP)

YearHBMHF PortfolioHBMHF Income/yrMO PortfolioMO Income/yrGap
1← crossover$23,521$12,820.51$10,570$780.30+$13.0KHBMHF
2$53,349$28,181.78$11,381$1,032.90+$42.0KHBMHF
3$116,823$59,739.54$12,535$1,392.73+$104.3KHBMHF
4$247,259$122,259.11$14,193$1,920.91+$233.1KHBMHF
5$506,405$241,837.18$16,618$2,723.68+$489.8KHBMHF
6$1,004,750$462,896.88$20,263$3,993.80+$984.5KHBMHF
7$1,933,425$858,342.70$25,936$6,098.36+$1.91MHBMHF
8$3,612,406$1,543,641.03$35,166$9,775.01+$3.58MHBMHF
9$6,560,727$2,695,452.74$51,026$16,597.78+$6.51MHBMHF
10$11,595,107$4,575,129.27$80,113$30,159.17+$11.51MHBMHF

HBMHF vs MO: Complete Analysis 2026

HBMHFStock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this HBMHF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs SCHDHBMHF vs JEPIHBMHF vs OHBMHF vs KOHBMHF vs MAINHBMHF vs PMHBMHF vs BTIHBMHF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.